Atai Beckley Inc.

NASDAQ:ATAI

Biotechnology

Healthcare
$7.35 -1.35%

-$0.06 today

Market cap
$2.72B
Beta
1.60
P/E (TTM)
-1.4
EPS (TTM)
-$2.93
52W Low $2.00High $6.75

Volume 0.00M

Average 5.68M

ATAI Sales of Investments

Cash received from selling or redeeming investments.

Atai Beckley Inc.NASDAQ: ATAI

Sales of Investments · Q2 FY2026 · quarter ended Jun 2026

Sales of investments outflow shrinks to $0

Q2 FY2026 sales of investments was $0, compared with $14.92M a year earlier. Trailing-twelve-month sales of investments was $3.72M. Over 3 fiscal years it compounded at -65.8% a year.

Context

  • Sales of investments amounted to 221.3% of revenue in FY2025, down 26405.9 pp from a year earlier.
  • Sales of investments increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly sales of investments holds near $0 or moves back toward the trailing-twelve-month quarterly average of $930.46K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$9.05M-89.0% YoY
LTMJun 2026
$3.72M+111.6% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-89.0%——
3-year CAGR-65.8%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
9.05M USD
Year-over-year change
-89.0%

Sales of Investments vs competitors

How ATAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +111.6% is the highest of 10, against a peer median of -5.8%.
  • Sales of investments amounts to 83.2% of revenue for ATAI, versus a peer median of 730.9%.
ATAI Competitors
Sales of Investments for ATAI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$459.13M USD+22.8%+16.3%211.4%
ELVNEnliven Therapeutics, Inc.LTM Sep 2026$387.14M USD+28.0%+86.8%—
NKTRNektar TherapeuticsLTM Jun 2026$384.71M USD+43.5%-29.9%704.7%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$369.36M USD-5.8%-3.9%3568.7%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$362.7M USD+47.6%+438.5%19049.4%
IMTXImmatics N.V.LTM Mar 2026€282.39M EUR-50.0%+246.5%757.1%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$228.84M USD-8.8%+11.1%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$225M USD-27.4%+24.5%—
SANASana Biotechnology, Inc.LTM Mar 2026$83.46M USD-65.5%-46.9%—
ATAIAtai Beckley Inc.LTM Jun 2026$3.72M USD+111.6%-65.8%83.2%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding ATAI) —-5.8%+16.3%730.9%

Competitors are the stored peer set for ATAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(174.24M)(157.42M)(43.9M)(150.05M)(660.05M)
Depreciation & Amortization47K168K319K473K1.01M
Deferred Income Tax39.14M5.07M000
Stock-Based Compensation63.36M42.38M32.98M25.49M0
Change in Working Capital(7.6M)(3.34M)7.47M(9.2M)(6.48M)
Accounts Receivables00000
Inventory00000
Accounts Payables2.3M(3.03M)2.14M(1.87M)(1.7M)
Other Working Capital(9.9M)(301K)5.33M(7.33M)(4.78M)
Other Non-Cash Items16.06M8.67M(80.99M)50.85M562.84M
Operating Cash Flow(63.25M)(104.47M)(84.12M)(82.44M)(102.68M)
Capital Expenditures(1.13M)(1.02M)(590K)(95K)(901K)
Acquisitions (Net)(52.94M)0(443K)359K4.64M
Purchases of Investments(23.66M)(309.66M)(186.22M)(15M)(98.95M)
Sales of Investments(955K)226.83M139.47M82.01M9.05M
Other Investing Activities(2.6M)(3.25M)(5.84M)(8.1M)(13M)
Investing Cash Flow(81.28M)(86.85M)(53.3M)59.17M(109.13M)
Debt Repayment1.59M15M05M7.71M
Common Stock Issued409.88M00535K283.43M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.42M5.19M(8.36M)(161K)(21.66M)
Financing Cash Flow409.86M20.79M(8.36M)5.37M269.48M
Effect of Forex Changes(320K)(1.12M)189K362K116K
Net Change in Cash265.02M(171.65M)(145.58M)(17.53M)57.8M
Free Cash Flow(64.37M)(105.49M)(84.71M)(82.53M)(103.58M)

Atai Beckley Inc.

NASDAQ:ATAI

Intrinsic Alpha fair value

Locked

Current Price

$7.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.